Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery. Issue 5 (16th May 2022)

• Record Type: Journal Article
• Authors: Song, Yihui; Yang, Xinyu; Wang, Shu; Zhao, Min; Yu, Bin
• Is Part Of: Medicinal research reviews. Volume 42:Issue 5(2022)
• Page Start: 1781
• Page End: 1821
• Publication Date: 2022-05-16
• Subjects: binding models -- drug discovery -- protein tyrosine phosphatase -- SHP2 inhibitors -- structural landscape; Pharmacology -- Periodicals; Drugs -- Research -- Periodicals; 615
• DOI: 10.1002/med.21890
• Languages: English
• ISSNs: 0198-6325

Abstract

Abstract: The protein tyrosine phosphatase SHP2 encoded by PTPN11 is a promising therapeutic target for cancer therapy. The dynamic change of SHP2 between closed and open conformations under either physiological or pathological conditions provides opportunities to design SHP2 inhibitors for treating SHP2‐related diseases. To date, several SHP2 allosteric inhibitors have advanced into clinical trials as mono‐ or combined therapy of cancers. In this review, we provide an overview on the structural landscape of SHP2 under physiological and pathological conditions and also comprehensively analyze the binding models of SHP2/inhibitor complexes. Structural features of SHP2 under pathological conditions and co‐crystal structures of SHP2/inhibitor complexes will definitely facilitate structure‐guided design of SHP2 inhibitors. Finally, proteolysis targeting chimeric (PROTAC) based SHP2 degraders have shown therapeutic promise for cancer therapy and are also briefly discussed. We hope this review could provide crystallographic landscape for SHP2 targeted drug discovery.